Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procter & Gamble

This article was originally published in The Rose Sheet

Executive Summary

Company confirms its sales and earnings guidance for the second quarter of fiscal year 2007, projecting sales growth of 5%-8% and organic sales growth of 4%-7%. The company will announce final results for the quarter Jan. 30, 2007. Q1 revenue increased 11% to $5.6 bil. due to growth across all categories, P&G said during Dec. 14 analyst call. Organic sales volume in the skin care division was up double digits, driven by the launch of Olay Definity and the performance of OlayRegenerist (1"The Rose Sheet" Nov. 6, 2006, p. 8)...

You may also be interested in...



P&G Q1 Beauty Sales Advance On Performance Of Olay, Pantene

Procter & Gamble beauty division revenues increased 11% to $5.6 bil. for the first quarter of fiscal year 2007 (ended Sept. 30), fueled by growth across all categories and the addition of Gillette products, the company reported in an Oct. 31 earnings release

Global Medtech Guidance Tracker: May 2020

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-one guidance documents have been posted on the tracker since its last update.

EU Health Program To Help Boost Post-Coronavirus Recovery

The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.

UsernamePublicRestriction

Register

SC142271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel